In their rapid risk assessment, EFSA scientists established an acute reference dose (ARfD) for cereulide in infants and identified cereulide concentrations in infant formula that are potentially relevant to safety.

The EFSA scientists proposed an ARfD of 0.014 μg/kg body weight for cereulide in infants. Emesis (vomiting) is the critical acute adverse effect used to establish the ARfD. As very young infants (under 16 weeks) metabolise substances differently than adults, EFSA took a cautious approach and added an additional safety factor when setting an ARfD.

EFSA issues rapid risk assessment on cereulide in infant formula